Interstitial Cystitis (Painful Bladder Syndrome) - Pipeline Review, H2 2016

Date: September 14, 2016
Pages: 90
Price:
US$ 2,000.00
License [?]:
Publisher: Global Markets Direct
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: I48027E3102EN
Leaflet:

Download PDF Leaflet

Interstitial Cystitis (Painful Bladder Syndrome) - Pipeline Review, H2 2016

Summary

Global Markets Direct’s, ‘Interstitial Cystitis (Painful Bladder Syndrome) - Pipeline Review, H2 2016’, provides an overview of the Interstitial Cystitis (Painful Bladder Syndrome) pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Interstitial Cystitis (Painful Bladder Syndrome), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Interstitial Cystitis (Painful Bladder Syndrome) and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope
  • The report provides a snapshot of the global therapeutic landscape of Interstitial Cystitis (Painful Bladder Syndrome)
  • The report reviews pipeline therapeutics for Interstitial Cystitis (Painful Bladder Syndrome) by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Interstitial Cystitis (Painful Bladder Syndrome) therapeutics and enlists all their major and minor projects
  • The report assesses Interstitial Cystitis (Painful Bladder Syndrome) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Interstitial Cystitis (Painful Bladder Syndrome)
Reasons to buy
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Interstitial Cystitis (Painful Bladder Syndrome)
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Interstitial Cystitis (Painful Bladder Syndrome) pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Introduction
Global Markets Direct Report Coverage
Interstitial Cystitis (Painful Bladder Syndrome) Overview
Therapeutics Development
Pipeline Products for Interstitial Cystitis (Painful Bladder Syndrome) - Overview
Pipeline Products for Interstitial Cystitis (Painful Bladder Syndrome) - Comparative Analysis
Interstitial Cystitis (Painful Bladder Syndrome) - Therapeutics under Development by Companies
Interstitial Cystitis (Painful Bladder Syndrome) - Therapeutics under Investigation by Universities/Institutes
Interstitial Cystitis (Painful Bladder Syndrome) - Pipeline Products Glance
Late Stage Products
Clinical Stage Products
Early Stage Products
Interstitial Cystitis (Painful Bladder Syndrome) - Products under Development by Companies
Interstitial Cystitis (Painful Bladder Syndrome) - Products under Investigation by Universities/Institutes
Interstitial Cystitis (Painful Bladder Syndrome) - Companies Involved in Therapeutics Development
Allergan Plc
Aquinox Pharmaceuticals Inc.
Astellas Pharma Inc.
Kytogenics Pharmaceuticals, Inc.
Lipella Pharmaceuticals, Inc.
MediPost Co., Ltd.
UCB S.A.
Urigen Pharmaceuticals, Inc.
UroGen Pharmaceuticals, Ltd.
Interstitial Cystitis (Painful Bladder Syndrome) - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
(heparin + lidocaine) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AQX-1125 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ASP-6294 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Cartistem - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
certolizumab pegol - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
GM-0111 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
lidocaine hydrochloride - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
LP-08 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
mesalamine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MK-7264 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NEO-5937 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
onabotulinumtoxinA - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
onabotulinumtoxinA SR - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
pentosan polysulfate sodium - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
URG-801 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Interstitial Cystitis (Painful Bladder Syndrome) - Dormant Projects
Interstitial Cystitis (Painful Bladder Syndrome) - Discontinued Products
Interstitial Cystitis (Painful Bladder Syndrome) - Product Development Milestones
Featured News & Press Releases
May 25, 2016: Aquinox Announces Executive Appointments
May 10, 2016: Aquinox Pharmaceuticals Announces First Quarter 2016 Financial Results
May 03, 2016: Allergan Presents New Data on LiRIS 400 mg at the American Urological Association Meeting in San Diego
Jan 11, 2016: Aquinox Announces Update on Development Program for AQX-1125 Following Meeting With FDA
Dec 22, 2015: Aquinox Pharmaceuticals Announces Appointment of Ms. Shelley McCloskey as Vice President, Human Resources & Administration
Sep 18, 2015: Aquinox Presents at 2015 International Society for the Study of BPS Conference
Aug 27, 2015: Lipella Pharmaceuticals Announces Enrollment of First Patient in Phase-2 Trial in Interstitial Cystitis
Aug 25, 2015: LEADERSHIP Results Accepted for Podium Presentation at the 2015 Annual Meeting of the International Society for the Study of BPS
Aug 06, 2015: Aquinox Pharmaceuticals Announces Positive Results From Secondary Endpoints From Phase 2 LEADERSHIP Trial in BPS/IC
Jul 28, 2015: Aquinox Pharmaceuticals to Provide Update on Secondary Endpoints From Phase 2 LEADERSHIP Trial in BPS/IC
Jun 25, 2015: Aquinox Pharmaceuticals Announces Results From LEADERSHIP Trial With AQX-1125 in Patients With Bladder Pain Syndrome/Interstitial Cystitis
May 18, 2015: Canadian Journal of Urology Study Highlights the Benefits of Heparin and Alkalinized Lidocaine Combination Formulation for the Relief of Interstitial Cystitis Symptoms
Mar 02, 2015: Aquinox Pharmaceuticals Completes Enrollment in the Phase 2 LEADERSHIP Trial of AQX-1125 in Bladder Pain Syndrome/Interstitial Cystitis
Feb 26, 2015: Afferent Clinical Data for Lead Candidate, AF-219, Demonstrate Improvements in Pain and Urinary Urgency in Interstitial Cystitis / Bladder Pain Syndrome
Jun 02, 2014: Aquinox Pharmaceuticals Announces Expansion of Ongoing Phase 2 Trials of AQX-1125, Including Acceptance of U.S. IND
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer 90

LIST OF TABLES

Number of Products under Development for Interstitial Cystitis (Painful Bladder Syndrome), H2 2016
Number of Products under Development for Interstitial Cystitis (Painful Bladder Syndrome) - Comparative Analysis, H2 2016
Number of Products under Development by Companies, H2 2016
Number of Products under Investigation by Universities/Institutes, H2 2016
Comparative Analysis by Late Stage Development, H2 2016
Comparative Analysis by Clinical Stage Development, H2 2016
Comparative Analysis by Early Stage Development, H2 2016
Products under Development by Companies, H2 2016
Products under Investigation by Universities/Institutes, H2 2016
Interstitial Cystitis (Painful Bladder Syndrome) - Pipeline by Afferent Pharmaceuticals, Inc., H2 2016
Interstitial Cystitis (Painful Bladder Syndrome) - Pipeline by Allergan Plc, H2 2016
Interstitial Cystitis (Painful Bladder Syndrome) - Pipeline by Aquinox Pharmaceuticals Inc., H2 2016
Interstitial Cystitis (Painful Bladder Syndrome) - Pipeline by Astellas Pharma Inc., H2 2016
Interstitial Cystitis (Painful Bladder Syndrome) - Pipeline by Kytogenics Pharmaceuticals, Inc., H2 2016
Interstitial Cystitis (Painful Bladder Syndrome) - Pipeline by Lipella Pharmaceuticals, Inc., H2 2016
Interstitial Cystitis (Painful Bladder Syndrome) - Pipeline by MediPost Co., Ltd., H2 2016
Interstitial Cystitis (Painful Bladder Syndrome) - Pipeline by UCB S.A., H2 2016
Interstitial Cystitis (Painful Bladder Syndrome) - Pipeline by Urigen Pharmaceuticals, Inc., H2 2016
Interstitial Cystitis (Painful Bladder Syndrome) - Pipeline by UroGen Pharmaceuticals, Ltd., H2 2016
Assessment by Monotherapy Products, H2 2016
Assessment by Combination Products, H2 2016
Number of Products by Stage and Target, H2 2016
Number of Products by Stage and Mechanism of Action, H2 2016
Number of Products by Stage and Route of Administration, H2 2016
Number of Products by Stage and Molecule Type, H2 2016
Interstitial Cystitis (Painful Bladder Syndrome) - Dormant Projects, H2 2016
Interstitial Cystitis (Painful Bladder Syndrome) - Discontinued Products, H2 2016 78

LIST OF FIGURES

Number of Products under Development for Interstitial Cystitis (Painful Bladder Syndrome), H2 2016
Number of Products under Development for Interstitial Cystitis (Painful Bladder Syndrome) - Comparative Analysis, H2 2016
Number of Products under Development by Companies, H2 2016
Comparative Analysis by Clinical Stage Development, H2 2016
Comparative Analysis by Early Stage Products, H2 2016
Assessment by Monotherapy Products, H2 2016
Number of Products by Targets, H2 2016
Number of Products by Stage and Targets, H2 2016
Number of Products by Mechanism of Actions, H2 2016
Number of Products by Stage and Mechanism of Actions, H2 2016
Number of Products by Routes of Administration, H2 2016
Number of Products by Stage and Routes of Administration, H2 2016
Number of Products by Molecule Types, H2 2016
Number of Products by Stage and Molecule Types, H2 2016
Skip to top


Interstitial Cystitis Therapy Area Pipeline Report US$ 1,495.00 Sep, 2010 · 73 pages

Ask Your Question

Interstitial Cystitis (Painful Bladder Syndrome) - Pipeline Review, H2 2016
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: